Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Triglycerides: early-phase trial registry

2 of 5 indexed Triglycerides trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Triglycerides: 5 US clinical trials tracked, 2 recruiting.

Triglycerides is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), running 2 of these trials.

Enrollment posture brief

Registry condition triglycerides

OPEN 2 | RECR 40% | LATE 0 | EARLY 1 | RANK #3391 | SPON 2

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Triglycerides (this)40%
Open-enrollment share among volume-matched conditions near Triglycerides

Triglycerides lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Triglycerides on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Triglycerides is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Triglycerides research.

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Triglycerides trials plan to enrol fewer than 100 people.

    Median target enrolment is 64 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Triglycerides splits between interventional and observational designs.

    3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Triglycerides records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

RDX-002 Drug
1 trials
Half Dose Curcumin (Longvida™) Dietary supplement
1 trials
Curcumin (Longvida™) Dietary supplement
1 trials
Comparator Other
1 trials
Bottarga Other
1 trials
Placebo Control Other
1 trials
Astaxanthin Dietary supplement
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Triglycerides trials. A trial with sites in several states counts in each.

Maryland 2 trials
Ohio 1 trials
Minnesota 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Triglycerides page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Triglycerides condition card totals 5 registered trials; most-linked intervention RDX-002; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.